<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Zolekar A</submitter><funding>NIA NIH HHS</funding><pagination>1538-1551</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC6288164</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>119(12)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Although NGLY1 is known as a pivotal enzyme that catalyses the deglycosylation of denatured glycoproteins, information regarding the responses of human cancer and normal cells to NGLY1 suppression is limited.&lt;h4>Methods&lt;/h4>We examined how NGLY1 expression affects viability, tumour growth, and responses to therapeutic agents in melanoma cells and an animal model. Molecular mechanisms contributing to NGLY1 suppression-induced anticancer responses were revealed by systems biology and chemical biology studies. Using computational and medicinal chemistry-assisted approaches, we established novel NGLY1-inhibitory small molecules.&lt;h4>Results&lt;/h4>Compared with normal cells, NGLY1 was upregulated in melanoma cell lines and patient tumours. NGLY1 knockdown caused melanoma cell de</pubmed_abstract><journal>British journal of cancer</journal><pubmed_title>Stress and interferon signalling-mediated apoptosis contributes to pleiotropic anticancer responses induced by targeting NGLY1.</pubmed_title><pmcid>PMC6288164</pmcid><funding_grant_id>T32 AG020494</funding_grant_id><pubmed_authors>Ho YY</pubmed_authors><pubmed_authors>Sampat R</pubmed_authors><pubmed_authors>Zolekar A</pubmed_authors><pubmed_authors>Liu J</pubmed_authors><pubmed_authors>Lin VJT</pubmed_authors><pubmed_authors>Emmitte KA</pubmed_authors><pubmed_authors>Hayatshahi HS</pubmed_authors><pubmed_authors>Liao X</pubmed_authors><pubmed_authors>Wang YC</pubmed_authors><pubmed_authors>Mishra NM</pubmed_authors><pubmed_authors>Hoffmann P</pubmed_authors><pubmed_authors>Parab A</pubmed_authors></additional><is_claimable>false</is_claimable><name>Stress and interferon signalling-mediated apoptosis contributes to pleiotropic anticancer responses induced by targeting NGLY1.</name><description>&lt;h4>Background&lt;/h4>Although NGLY1 is known as a pivotal enzyme that catalyses the deglycosylation of denatured glycoproteins, information regarding the responses of human cancer and normal cells to NGLY1 suppression is limited.&lt;h4>Methods&lt;/h4>We examined how NGLY1 expression affects viability, tumour growth, and responses to therapeutic agents in melanoma cells and an animal model. Molecular mechanisms contributing to NGLY1 suppression-induced anticancer responses were revealed by systems biology and chemical biology studies. Using computational and medicinal chemistry-assisted approaches, we established novel NGLY1-inhibitory small molecules.&lt;h4>Results&lt;/h4>Compared with normal cells, NGLY1 was upregulated in melanoma cell lines and patient tumours. NGLY1 knockdown caused melanoma cell de</description><dates><release>2018-01-01T00:00:00Z</release><publication>2018 Dec</publication><modification>2026-05-05T22:16:28.204Z</modification><creation>2019-07-25T07:11:38Z</creation></dates><accession>S-EPMC6288164</accession><cross_references><pubmed>30385822</pubmed><doi>10.1038/s41416-018-0265-9</doi></cross_references></HashMap>